StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen UPLIZNA (inebilizumab-cdon by Quarter

UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — Rest of World (ROW) product sales ($M) ($M)

QuarterlyAnnual

Amgen UPLIZNA (inebilizumab-cdon: $18M in Q2 2026, down 59.1% from a year earlier.

Latest, Q2 2026
18
Period ended Jun 30, 2026
Change on a year earlier
-59.1%
44 in Q2 2025
History
11 quarters
Since Q4 2023
Sources
9
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — Rest of World (ROW) product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202618-59.1%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 202616+77.8%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 202565+712.5%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 20259-71.9%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 202544+193.3%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20259-10.0%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 20248+60.0%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202432–Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202415–Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 202410–Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 20235–Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗

Cite this data

StockData. (2026). Amgen UPLIZNA (inebilizumab-cdon ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-uplizna-row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.